

# DRUG METABOLISM AND DISPOSITION

Gene symbol	Name	Human hepatocytes	Differentiated HepaRG	Differentiated HepaRG cultured w/o DMSO for 1d	Differentiated HepaRG cultured w/o DMSO for 5d	Differentiated HepaRG cultured w/o DMSO for 14d
CYP1A1	CYP1A1					
CYP1A2	CYP1A2					
CYP2A6	CYP2A6					
CYP2B6	CYP2B6					
CYP2C8	CYP2C8					
CYP2C9	CYP2C9					
CYP2C19	CYP2C19					
CYP2D6	CYP2D6					
CYP2E1	CYP2E1					
CYP3A4	CYP3A4					
CYP3A7	CYP3A7					
CYP7A1	CYP7A1					
GSTA1	GSTA1					
SULT2A1	SULT2A1					
UGT2B7	UGT2B7					
SLCO2B1	OATP2B1					
SLCO1B1	OATP1B1					
SLCO1B3	OATP1B3					
SLC22A7	SLC22A7					
SLC22A1	SLC22A1					
SLC10A1	SLC10A1					
SLC15A1	SLC15A1					
ABCB1	MDR1					
ABCB4	MDR3					
ABCC1	MRP1					
ABCC2	MRP2					
ABCC3	MRP3					
ABCB11	BSEP					
ABCG2	BCRP					
NR1I2	PXR					
NR1I3	CAR					
AHR	AhR					
NR1H4	FXR					
RXRA	RXR $\alpha$					
RXRB	RXR $\beta$					
HNF4A	HNF4 $\alpha$					
CEBPA	CEBP $\alpha$					
CEBPB	CEBP $\beta$					
AFP	Alpha fetoprotein					
ALB	Albumin					
DBP	D site-binding protein					
G6PC3	Glucose-6-phosphatase					
GATA4	Transcription factor GATA-4					
TTR	Transthyretin					

  

N.D.	0.0001-0.01	0.01-0.2	0.2-0.8	0.8-1.2	1.2-2	2.0-5.0	>5.0
------	-------------	----------	---------	---------	-------	---------	------

A Publication of the  
American Society for Pharmacology  
and Experimental Therapeutics

# **Drug Metabolism and Disposition**

**Volume 36**

**Number 7**

**July 2008**

**Pages 1189-1452**

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

Founded by Kenneth C. Leibman—1973

**Eric F. Johnson, Editor**

## ASSOCIATE EDITORS

Stephen D. Hall, Laurence S. Kaminsky, Russell A. Prough, John D. Schuetz, Jeffrey C. Stevens,  
Kenneth E. Thummel, Donald J. Tweedie, Steven A. Wrighton, and Garold S. Yost

## SCIENTIFIC ADVISORY BOARD

M.W. Anders, Minor J. Coon, Ronald W. Estabrook, Frederick P. Guengerich  
James R. Halpert, Anthony Y. Lu, Bettie Sue Masters, and Paul R. Ortiz De Montellano

## EDITORIAL BOARD MEMBERS

Tommy B. Andersson	Cornelis J. Elferink	Jeffrey P. Jones	R. Scott Obach	Bill J. Smith
Wayne L. Backes	Michael R. Franklin	Richard Kim	K. Sandy Pang	Grazyna D. Szklarz
Thomas Baillie	Ronald B. Franklin	Sang Geon Kim	Anna Radomska-Pandya	Yun K. Tam
John R. Bend	Joyce Goldstein	Thomas Kocarek	Judy L. Raucy	Timothy S. Tracy
Jeffrey L. Blumer	Robert Hanzlik	Dennis R. Koop	Allan Rettie	Mary Vore
Kim L.R. Brouwer	Ronald N. Hines	Lawrence H. Lash	Douglas Rickert	Paul B. Watkins
Arthur Cederbaum	Paul F. Hollenberg	J. Steven Leeder	David S. Riddick	David J. Waxman
Nathan Cherrington	J. Brian Houston	Lois D. Lehman-McKeeman	Joseph K. Ritter	Ronald E. White
Arthur K. Cho	Magnus Ingelman-Sundberg	Peter Ian Mackenzie	A. David Rodrigues	Larry C. Wienkers
David D. Christ	Philip B. Inskip	Edward T. Morgan	Melissa Runge-Morris	Paul Wissel
Deepak Dalvie	Margaret O. James	Sidney D. Nelson	Magang Shou	Yasushi Yamazoe
William J. Ehlhardt				Cheryl L. Zimmerman
Sean Ekins				

## BOARD OF PUBLICATIONS TRUSTEES

James E. Barrett, *Chair*; P. Jeffrey Conn, Ross Feldman, Lorraine J. Gudas, Eric F. Johnson, John S. Lazo, Edward T. Morgan,  
Richard R. Neubig, Rick G. Schnellmann, Darryle D. Schoepp, and Mary Vore

**ASPET EXECUTIVE OFFICER:** Christine K. Carrico

*Journals Director:* Richard Dodenhoff

*Managing Editor:* Jill Filler

*Senior Editorial Coordinator:* Rhonda Frankenfield

**Journal and ASPET office:** 9650 Rockville Pike, Bethesda, MD 20814-3995; telephone: 301-634-7060; fax: 301-634-7061; email: info@aspet.org; web site: www.aspet.org; journal web site: dmd.aspetjournals.org.

**Editorial matters** should be addressed to Dr. Eric F. Johnson, Editor, *Drug Metabolism and Disposition*, at the above address.

**Official version:** The online version of *Drug Metabolism and Disposition* contains all of the information and material contained in the print version plus additional material that may not appear in print such as videos and large data sets. The online version may be more current than the print version. Where noted, the online version has been corrected in departure from the print version. The online version of *Drug Metabolism and Disposition* officially published by the American Society for Pharmacology and Experimental Therapeutics is the definitive version and, to the extent any difference exists, will prevail over the print version.

**Instructions to Authors:** See [jpet.aspetjournals.org](http://jpet.aspetjournals.org) for the Instructions to Authors and the ASPET Authorship Responsibility, Financial Disclosure, and Copyright Transfer form.

**Subscriptions:** Contact the ASPET Subscriptions Dept., 9650 Rockville Pike, Bethesda, MD 20814-3995; telephone: 301-634-7782; fax: 301-634-7061; email: [subscriptions@aspet.org](mailto:subscriptions@aspet.org). For multi-site and consortia sales in Europe, contact: David Charles, eLicensing, 92 avenue du Général de Gaulle, 78600, Maisons-Laffitte, France; telephone: +33-1-39-12-29-29; fax: +33-1-39-12-47-45; email: [dc.licensing@organge.fr](mailto:dc.licensing@organge.fr).

**Change of address:** ASPET must be notified 60 days in advance. Copies undeliverable because of incorrect address will be destroyed. Duplicate copies may be obtained, if available, from ASPET at the single copy price. Send address changes to the ASPET office.

**Issue replacement policy:** *Domestic subscribers*—Claims for nondelivery of issues must be made within three (3) months of issue mail date. *Foreign subscribers*—Claims for nondelivery of issues must be made within six (6)

months of issue mail date. **Missing Issues (domestic and foreign)**—ASPET will not honor refunds or replacement requests made outside of the claim time period. Up to two (2) issues will be replaced free of charge per subscription year.

**Reprints in large quantities** for commercial or academic use may be purchased from ASPET. For information and prices, call 301-634-7063.

**Copyright information:** *Drug Metabolism and Disposition* is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. For permission to photocopy or use material electronically from *Drug Metabolism and Disposition*, see [www.copyright.com](http://www.copyright.com) or contact the Copyright Clearance Center (CCC), Inc., 222 Rosewood Dr., Danvers, MA 01923; telephone: 978-750-8400. Photocopying of articles beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law is allowed, provided that the \$20.00-per-copy fee is paid through the CCC. Classroom photocopying is permitted at no fee, provided that students are not charged more than the cost of duplication. This consent does not extend to other kinds of copying. Reproduction of any portion of an article for subsequent republication requires permission of ASPET. Write to the ASPET office at the above address. Requests should include a statement of intended use as well as explicit specifications of the materials to be reproduced.

**Disclaimer:** The statements and opinions contained in the articles of *Drug Metabolism and Disposition* are solely those of the individual authors and contributors and not of the American Society for Pharmacology and Experimental Therapeutics. The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or their safety. The American Society for Pharmacology and Experimental Therapeutics disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in any article or advertisement.

**Copyright** © 2008 by the American Society for Pharmacology and Experimental Therapeutics. All rights reserved. Printed in the U.S.A.

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

July 2008

Vol. 36, No. 7

## CONTENTS

### SHORT COMMUNICATIONS

- The Antiapoptotic Factor Growth Arrest and DNA-Damage-Inducible 45  $\beta$  Regulates the Nuclear Receptor Constitutive Active/Androstane Receptor-Mediated Transcription. *Yukio Yamamoto and Masahiko Negishi* . . . . . **1189**

- Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data. *Peter J. Kilford, Michael Gertz, J. Brian Houston, and Aleksandra Galetin* . . . . . **1194**

- An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug Interaction. *Melinda J. Reese, Robert M. Wurm, Keith T. Muir, Grant T. Generaux, Lisa St. John-Williams, and Donavon J. McConn* . . . . . **1198**

- Aldehyde Oxidase-Catalyzed Metabolism of  $N^1$ -Methylnicotinamide in Vivo and in Vitro in Chimeric Mice with Humanized Liver. *Shigeyuki Kitamura, Kayoko Nitta, Yoshitaka Tayama, Chiaki Tanoue, Kazumi Sugihara, Tae Inoue, Toru Horie, and Shigeru Ohta* . . . . . **1202**

- Inhibitory Effects of Terpenoids on Multidrug Resistance-Associated Protein 2- and Breast Cancer Resistance Protein-Mediated Transport. *Naoko Yoshida, Tappei Takada, Yoshikazu Yamamura, Isao Adachi, Hiroshi Suzuki, and Junichi Kawakami* . . . . . **1206**

### ARTICLES

- Osmotic Regulation of a Novel Flavin-Containing Monooxygenase in Primary Cultured Cells from Rainbow Trout (*Oncorhynchus mykiss*). *Gabriela Rodríguez-Fuentes, Rosaura Aparicio-Fabre, Qi Li, and Daniel Schlenk* . . . . . **1212**

- Disposition of Lasofoxifene, a Next-Generation Selective Estrogen Receptor Modulator, in Healthy

- Male Subjects. *Chandra Prakash, Kim A. Johnson, and Mark J. Gardner* . . . . . **1218**

- The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2. *Eric T. Williams, Karen O. Jones, G. Douglas Ponsler, Shane M. Lowery, Everett J. Perkins, Steven A. Wrighton, Kenneth J. Ruterbories, Miho Kazui, and Nagy A. Farid* . . . . . **1227**

- Pharmacokinetic Parameters of Chlorzoxazone and Its Main Metabolite, 6-Hydroxychlorzoxazone, after Intravenous and Oral Administration of Chlorzoxazone to Liver Cirrhotic Rats with Diabetes Mellitus. *Choong Y. Ahn, Soo K. Bae, Young S. Jung, Inchul Lee, Young C. Kim, Myung G. Lee, and Wan G. Shin* . . . . . **1233**

- Differential Genotype Dependent Inhibition of CYP2C9 in Humans. *Vikas Kumar, Richard C. Brundage, William S. Oetting, Ilo E. Leppik, and Timothy S. Tracy* . . . . . **1242**

- Closing the Gaps: A Full Scan of the Intestinal Expression of P-Glycoprotein, Breast Cancer Resistance Protein, and Multidrug Resistance-Associated Protein 2 in Male and Female Rats. *Caroline MacLean, Ulla Moenning, Andreas Reichel, and Gert Fricker* . . . . . **1249**

- Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. II. In Vitro-in Vivo Correlation with Ketoconazole. *Chuang Lu, Panos Hatsis, Cicely Berg, Frank W. Lee, and Suresh K. Balani* . . . . . **1255**

- Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. III. In Vitro-in Vivo Correlation with Fluconazole. *Chuang Lu, Cicely Berg, Shimoga R. Prakash, Frank W. Lee, and Suresh K. Balani* . . . . . **1261**

Continued on next page



Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models. <i>Shinji Yamazaki, Judith Skaptason, David Romero, Joseph H. Lee, Helen Y. Zou, James G. Christensen, Jeffrey R. Koup, Bill J. Smith, and Tatiana Koudriakova</i> . .	1267	thony Barros, Jr., Vinod K. Arora, Haiying Zhang, Lifei Wang, Donglu Zhang, James A. Manning, Kan He, Anthony M. Fletcher, Marc Ogan, Michael Lago, Samuel J. Bonacorsi, W. Griffith Humphreys, and Ramaswamy A. Iyer . .	1341
Effect of Plasma Protein Binding on in Vitro-in Vivo Correlation of Biliary Excretion of Drugs Evaluated by Sandwich-Cultured Rat Hepatocytes. <i>Hajime Fukuda, Rikiya Ohashi, Minoru Tsuda-Tsukimoto, and Ikumi Tamai</i> . . . . .	1275	Metabolism and Disposition of Dasatinib after Oral Administration to Humans. <i>Lisa J. Christopher, Donghui Cui, Chiyuan Wu, Roger Luo, James A. Manning, Samuel J. Bonacorsi, Michael Lago, Alban Allentoff, Francis Y. F. Lee, Betty McCann, Susan Galbraith, Donald P. Reitberg, Kan He, Anthony Barros, Jr., Anne Blackwood-Chirchir, W. Griffith Humphreys, and Ramaswamy A. Iyer</i> . . . . .	1357
Effects of Spice Constituents on P-Glycoprotein-Mediated Transport and CYP3A4-Mediated Metabolism in Vitro. <i>Wenxia Zhang and Lee-Yong Lim</i> . . . .	1283	[S] Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes. <i>Stuart W. Paine, Alison J. Parker, Philip Gardiner, Peter J. H. Webborn, and Robert J. Riley</i> . . . .	1365
The Mibefradil Derivative NNC55-0396, a Specific T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 Inhibition than Mibefradil. <i>Peter H. Bui, Arnulfo Quesada, Adrian Handforth, and Oliver Hankinson</i> . . . . .	1291	Rate-Limiting Steps in Hepatic Drug Clearance: Comparison of Hepatocellular Uptake and Metabolism with Mitochondrial Metabolism of Saquinavir, Nelfinavir, and Ritonavir. <i>Alison J. Parker and J. Brian Houston</i> . . . . .	1375
Drug Transporter and Cytochrome P450 mRNA Expression in Human Ocular Barriers: Implications for Ocular Drug Disposition. <i>Tao Zhang, Cathie D. Xiang, David Gale, Samantha Carreiro, Ellen Y. Wu, and Eric Y. Zhang</i> . . . . .	1300	[S] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds. <i>R. Scott Obach, Franco Lombardo, and Nigel J. Waters</i> . . . . .	1385
Inhibitory Effects of Seven Components of Danshen Extract on Catalytic Activity of Cytochrome P450 Enzyme in Human Liver Microsomes. <i>Furong Qiu, Rong Zhang, Jianguo Sun, Jiye A, Haiping Hao, Ying Peng, Hua Ai, and Guangji Wang</i> . . . . .	1308	Use of Online Microdialysis Sampling to Determine the in Vivo Rate of Phenol Glucuronidation in Rainbow Trout. <i>John W. Nichols, Alex D. Hoffman, Patrick N. Fitzsimmons, Gregory J. Lien, and Correne T. Jenson</i> . . . . .	1406
Cellular Accumulation of Cholesteryl-Glycylamido-Fluorescein in Sandwich-Cultured Rat Hepatocytes: Kinetic Characterization, Transport Mechanisms, and Effect of Human Immunodeficiency Virus Protease Inhibitors. <i>Zhi-wei Ye, Patrick Augustijns, and Pieter Annaert</i> . . . . .	1315	In Silico Methods for Unraveling the Mechanistic Complexities of Intestinal Absorption: Metabolism-Efflux Transport Interactions. <i>Lana X. Garmire and C. Anthony Hunt</i> . . . . .	1414
[S] Functional Expression and Comparative Characterization of Nine Murine Cytochromes P450 by Fluorescent Inhibition Screening. <i>Lesley A. McLaughlin, Leslie J. Dickmann, C. Roland Wolf, and Colin J. Henderson</i> . . . . .	1322	[S] Bioactivation of Flutamide Metabolites by Human Liver Microsomes. <i>Ping Kang, Deepak Dalvie, Evan Smith, Sue Zhou, Alan Deese, and James A. Nieman</i> . . . . .	1425
Comparative Analysis of CYP3A Heteroactivation by Steroid Hormones and Flavonoids in Different in Vitro Systems and Potential in Vivo Implications. <i>Jamie Henshall, Aleksandra Galetin, Anthony Harrison, and J. Brian Houston</i> . . . . .	1332	Down-Regulation of a Hepatic Transporter Multidrug Resistance-Associated Protein 2 Is Involved in Alteration of Pharmacokinetics of Glycyrrhizin and Its Metabolites in a Rat Model of Chronic Liver Injury. <i>Toshiaki Makino, Nobuhiro Ohtake, Akito Watanabe, Naoko Tsuchiya, Sachiko Imamura, Seiichi Iizuka, Makoto Inoue, and Hajime Mizukami</i> . . .	1438
Biotransformation of [ <sup>14</sup> C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys. <i>Lisa J. Christopher, Donghui Cui, Wenying Li, An-</i>		[S] Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies. <i>Kajsa P. Kanebratt and Tommy B. Andersson</i> . . . . .	1444

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Expression of mRNA for 44 genes in cryopreserved human hepatocytes and in differentiated HepaRG cells cultured with and without dimethyl sulfoxide ( $n = 3$ , human hepatocyte batches 1, 4, and 5). See article by Kanebratt and Andersson on page 1444 of this issue.